{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisolone+Sodium+Phosphate+Ophthalmic+Solution+1%25&page=2",
    "query": {
      "intervention": "Prednisolone Sodium Phosphate Ophthalmic Solution 1%",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 38,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisolone+Sodium+Phosphate+Ophthalmic+Solution+1%25&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisolone+Sodium+Phosphate+Ophthalmic+Solution+1%25&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T02:17:18.543Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06365853",
      "title": "A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Ovarian Cancer",
        "Folate Receptor-Alpha Positive"
      ],
      "interventions": [
        {
          "name": "Mirvetuximab Soravtansine",
          "type": "DRUG"
        },
        {
          "name": "Lubricating Eye Drops",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone acetate ophthalmic suspension 1% eye drops",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine tartrate ophthalmic solution eye drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 108,
      "start_date": "2024-07-29",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-12T02:17:18.543Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • San Francisco, California • Louisville, Kentucky + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06365853"
    },
    {
      "nct_id": "NCT00758199",
      "title": "Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cataracts"
      ],
      "interventions": [
        {
          "name": "Bromfenac",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bp Consulting, Inc",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 49,
      "start_date": "2008-07",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-10-12T02:17:18.543Z",
      "location_count": 1,
      "location_summary": "Los Altos, California",
      "locations": [
        {
          "city": "Los Altos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00758199"
    },
    {
      "nct_id": "NCT01505088",
      "title": "Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anterior Uveitis"
      ],
      "interventions": [
        {
          "name": "40 mg/mL Dexamethasone phosphate ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Acetate (1%) Eyedrops",
          "type": "DRUG"
        },
        {
          "name": "100 mM sodium citrate buffer solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Eyedrops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eyegate Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "12 Years to 85 Years"
      },
      "enrollment_count": 193,
      "start_date": "2011-12",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2013-03-29",
      "last_synced_at": "2026-10-12T02:17:18.543Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01505088"
    },
    {
      "nct_id": "NCT00698724",
      "title": "Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cataracts"
      ],
      "interventions": [
        {
          "name": "Xibrom, and Optive",
          "type": "DRUG"
        },
        {
          "name": "Xibrom and Pred Forte",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bp Consulting, Inc",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2008-06",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2009-06-10",
      "last_synced_at": "2026-10-12T02:17:18.543Z",
      "location_count": 1,
      "location_summary": "Tarpon Springs, Florida",
      "locations": [
        {
          "city": "Tarpon Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00698724"
    },
    {
      "nct_id": "NCT01769352",
      "title": "Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Post-surgical Cystoid Macular Edema (PSCME)"
      ],
      "interventions": [
        {
          "name": "PredA + Kelac",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2012-08",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-09-15",
      "last_synced_at": "2026-10-12T02:17:18.543Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01769352"
    },
    {
      "nct_id": "NCT01730872",
      "title": "Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Prednisolone Sodium Phosphate Ophthalmic Solution 1%",
          "type": "DRUG"
        },
        {
          "name": "Tears Naturale II Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ORA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2012-11",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2019-06-19",
      "last_synced_at": "2026-10-12T02:17:18.543Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01730872"
    },
    {
      "nct_id": "NCT04501367",
      "title": "Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Vitrectomy",
        "Macular Pucker",
        "Retinal Edema"
      ],
      "interventions": [
        {
          "name": "Dexamethasone Intracanalicular Insert, 0.4 mg",
          "type": "DRUG"
        },
        {
          "name": "Prednisone acetate 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kovach Eye Institute",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2021-04-27",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-06-29",
      "last_synced_at": "2026-10-12T02:17:18.543Z",
      "location_count": 1,
      "location_summary": "Elmhurst, Illinois",
      "locations": [
        {
          "city": "Elmhurst",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04501367"
    },
    {
      "nct_id": "NCT04168112",
      "title": "Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Keratoconus, Unstable",
        "Collagen Crosslinking",
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "Dextenza",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sight Medical Doctors PLLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2020-02-12",
      "completion_date": "2023-04-05",
      "has_results": true,
      "last_update_posted_date": "2024-01-30",
      "last_synced_at": "2026-10-12T02:17:18.543Z",
      "location_count": 1,
      "location_summary": "Babylon, New York",
      "locations": [
        {
          "city": "Babylon",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04168112"
    },
    {
      "nct_id": "NCT06765980",
      "title": "A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Geographic Atrophy Secondary to Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "VV-14295",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Kriya Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "55 Years to 80 Years"
      },
      "enrollment_count": 62,
      "start_date": "2025-05-28",
      "completion_date": "2027-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-12T02:17:18.543Z",
      "location_count": 1,
      "location_summary": "Erie, Pennsylvania",
      "locations": [
        {
          "city": "Erie",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06765980"
    },
    {
      "nct_id": "NCT02406209",
      "title": "A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-infectious Anterior Uveitis"
      ],
      "interventions": [
        {
          "name": "NS2",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone acetate ophthalmic suspension (1%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aldeyra Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 45,
      "start_date": "2015-03",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2023-03-27",
      "last_synced_at": "2026-10-12T02:17:18.543Z",
      "location_count": 15,
      "location_summary": "Lancaster, California • Golden, Colorado • Hamden, Connecticut + 12 more",
      "locations": [
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Ayer",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02406209"
    }
  ]
}